(0.33%) 5 116.70 points
(0.33%) 38 364 points
(0.36%) 15 986 points
(-0.94%) $83.06
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.03%) $959.30
(-0.25%) $0.932
(-0.41%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases...
Stats | |
---|---|
本日の出来高 | 17 954.00 |
平均出来高 | 9 422.00 |
時価総額 | 2.61M |
EPS | €0 ( 2024-04-16 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.0600 |
ATR14 | €0 (0.00%) |
Biophytis SA American 相関
10 最も正の相関 | |
---|---|
SERA | 0.952 |
BAOS | 0.934 |
LEXX | 0.932 |
PBHC | 0.924 |
OPOF | 0.922 |
WNEB | 0.913 |
PEBK | 0.911 |
HWBK | 0.911 |
CBFV | 0.909 |
QNST | 0.908 |
10 最も負の相関 | |
---|---|
ENNVU | -0.975 |
ENVI | -0.954 |
GOODM | -0.901 |
MSFT | -0.899 |
GXII | -0.898 |
ISRG | -0.898 |
AQST | -0.897 |
BLRX | -0.897 |
APEI | -0.896 |
ISEE | -0.896 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Biophytis SA American 財務諸表
Annual | 2023 |
収益: | €0 |
総利益: | €-803 000 (0.00 %) |
EPS: | €-0.0314 |
FY | 2023 |
収益: | €0 |
総利益: | €-803 000 (0.00 %) |
EPS: | €-0.0314 |
FY | 2022 |
収益: | €0 |
総利益: | €-484 000 (0.00 %) |
EPS: | €-0.130 |
FY | 2021 |
収益: | €0.00 |
総利益: | €0.00 (0.00 %) |
EPS: | €-2.60 |
Financial Reports:
No articles found.
Biophytis SA American
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。